

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GREATVIEW ASEPTIC PACKAGING COMPANY LIMITED

紛美包裝有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 00468)

CHANGES TO THE BOARD AND CHANGES TO THE BOARD COMMITTEES OF THE COMPANY

The Board announces the following changes:

(1) Mr. CHEN Weishu has notified the Board that due to his compliance with the requirements of certain directions imposed in the People’s Republic of China, he decided not to offer himself for re-election after his retirement by rotation at the 2015 AGM and accordingly he will retire as an independent non-executive director of the Company by rotation at the 2015 AGM. Mr. Chen will resign as the chairman of the Remuneration Committee, members of the Audit Committee and the Nomination Committee upon his retirement from the Board, effective from the conclusion of the 2015 AGM; and

(2) Mr. DANG Xinhua will be appointed as an independent non-executive director of the Company, chairman of the Remuneration Committee, members of the Audit Committee and the Nomination Committee with effect from the conclusion of the 2015 AGM.

The board of directors (the “**Board**”) of Greatview Aseptic Packaging Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces the following changes to the Board below.

RETIREMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND RESIGNATION OF CHAIRMAN OF THE REMUNERATION COMMITTEE, MEMBERS OF THE AUDIT COMMITTEE AND THE NOMINATION COMMITTEE

Mr. CHEN Weishu (“**Mr. Chen**”) has notified the Board that due to his compliance with the requirements of relevant directions imposed in the People’s Republic of China, he decided not to offer himself for re-election after his retirement by rotation at the 2015 annual general meeting of the Company to be held on 29 May 2015 (the “**2015 AGM**”) and accordingly he will retire as an independent non-executive director of the Company by rotation at the 2015 AGM.

Mr. Chen is currently the chairman of the remuneration committee of the Company (the “**Remuneration Committee**”) and a member of each of the audit committee (the “**Audit Committee**”) and the nomination committee (the “**Nomination Committee**”) of the Company. Mr. Chen will resign from the above board committees upon his retirement from the Board, effective from the conclusion of the 2015 AGM.

Mr. Chen has confirmed that he has no disagreement with the Board and there is no matter relating to his retirement that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to take this opportunity to express its gratitude and appreciation to Mr. Chen for his valuable contribution and support to the Company, and his efforts in safeguarding the interests of the Company and its shareholders during his term of services.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHAIRMAN OF THE REMUNERATION COMMITTEE, MEMBERS OF THE AUDIT COMMITTEE AND THE NOMINATION COMMITTEE

The Board is pleased to announce that Mr. DANG Xinhua (黨新華)(“**Mr. Dang**”) will be appointed as an independent non-executive director of the Company with effect from the conclusion of the 2015 AGM. Mr. Dang will also be appointed as the chairman of the Remuneration Committee and a member of each of the Audit Committee and the Nomination Committee with effect from the conclusion of the 2015 AGM.

The biographies of Mr. Dang are set out below:

Mr. Dang, aged 61, is the chairman and founding partner of the China business of a global executive search firm, Odgers Berndtson. Prior to that, he was with Russell Reynolds Associates in Hong Kong for over eight years. He was one of the first Chinese nationals to enter the executive search business in China in 1994. Mr. Dang was formerly an independent director of 北京雙鶴藥業股份有限公司 (*Beijing Double-Crane Pharmaceutical Co., Ltd.) (now known as 華潤雙鶴藥業股份有限公司 (*China Resources Double-Crane Pharmaceutical Co., Ltd.)), which is listed on the Shanghai Stock Exchange (stock code: 600062), until 31 May 2012. He is currently an advisor to the United States Business Council for Sustainable Development (美國可持續發展工商理事會) in their activities in China. Mr. Dang graduated from Hunan University, China and received his Master's degree in International Business from Columbia University in the United States.

Mr. Dang has entered into an appointment letter with the Company for his appointment as an independent non-executive director of the Company for a fixed term of two years commencing from 29 May 2015, which is terminable by either party thereto giving to the other party not less than three months' notice in writing and is subject to retirement by rotation in accordance with the articles of association of the Company. Under the appointment letter, Mr. Dang is entitled to an annual emolument of HK\$180,000 and a Board meeting attendance fee at a rate of HK\$5,000 per Board meeting capped at HK\$20,000 per annum. His annual emolument is determined by the Board based on the recommendation of the Remuneration Committee with reference to the scope of responsibility and his experience, taking into consideration of the prevailing market conditions.

Save as disclosed above, Mr. Dang (i) does not hold any other positions with the Group (ii) does not have other major appointments and professional qualifications; (iii) does not have any interest or short positions in any shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (iv) does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders of the Company.

Mr. Dang has confirmed that he meets the independence criteria as set out in Rule 3.13 of the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**").

Save as disclosed above, there are no other matters required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules or any other matters that need to be brought to the attention of the shareholders of the Company.

The Board would like to express its warmest welcome to Mr. Dang on his appointment.

SUPPLEMENTAL CIRCULAR, SUPPLEMENTAL NOTICE OF 2015 AGM AND THE SECOND FORM OF PROXY

In view of the above-mentioned retirement of Mr. Chen Weishu, who was originally

being proposed for re-election as an independent non-executive director of the Company at the 2015 AGM, the Company shall withdraw the originally proposed resolution regarding the re-election of Mr. Chen as contained in the notice of the 2015 AGM dated 24 April 2015. A supplemental circular, supplemental notice of the 2015 AGM and the second form of proxy will be dispatched to the shareholders of the Company shortly.

By order of the Board
Greatview Aseptic Packaging Company Limited
BI Hua, Jeff
Chief Executive Officer and Executive Director

Beijing, the PRC, 11 May 2015

As at the date of this announcement, the Board comprises two executive directors, namely BI Hua, Jeff and LIU Jun; two non-executive directors, namely HONG Gang and ZHU Jia; and three independent non-executive directors, namely LUETH Allen Warren, BEHRENS Ernst Hermann and CHEN Weishu.